Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses

Yan Chang, Yujing Wu, Di Wang, Wei Wei, Qiong Qin, Guoxiong Xie, Lingling Zhang, Shangxue Yan, Jingyu Chen, Qingtong Wang, Huaxun Wu, Feng Xiao, Wuyi Sun, Juan Jin, Wenxiang Wang

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Objective: To investigate the effects of TACI-Ig, a recombinant fusion protein that modulates B- and T-cell activation by binding and neutralizing B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), in an established adjuvant-induced arthritis (AA) rat model. Methods: Rats with experimental arthritis were randomly separated into different groups and then treated with TACI-Ig (0.7, 2.1, 6.3 mg/kg), rhTNFR-Fc (2.8 mg/kg), MTX (0.5 mg/kg) or IgG-Fc (6.3 mg/kg), from Day 16 to Day 34 after immunization. Arthritis was evaluated by hind paw swelling, polyarthritis index and histopathological examination. Activities of BLyS, APRIL, IL-1β, IL-2, IL-10, TGF-β1, PGE 2, TNF-α, IFN-γ, immunoglobulin (Ig)G1, IgG2a, IgM and IgA were assessed by ELISA. Cluster of differentiation (CD)20 expression was detected by immunohistochemical analysis. Results: TACI-Ig (2.1, 6.3 mg/kg) treatment significantly reduced the severity of established arthritis using the methods of clinical observation and histopathological examination. TACI-Ig treatment inhibited expression of IgM, decreased the expression of BLyS and APRIL and regulated the balance of pro-inflammatory and anti-inflammatory cytokines in serum of AA rats. Immunohistochemical analysis demonstrated that CD20 production was reduced in spleen. Conclusions: Data presented here demonstrate that administration of TACI-Ig significantly attenuates progression of experimental arthritis, with reductions in inflammatory response and bone and joint destruction.

Original languageEnglish (US)
Article numberkeq404
Pages (from-to)862-870
Number of pages9
JournalRheumatology
Volume50
Issue number5
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

Experimental Arthritis
Therapeutic Uses
Immunoglobulins
B-Cell Activating Factor
Arthritis
Ligands
Immunoglobulin M
Recombinant Fusion Proteins
Prostaglandins E
Interleukin-1
Interleukin-10
Immunoglobulin A
Interleukin-2
Immunization
Anti-Inflammatory Agents
Spleen
Immunoglobulin G
Joints
Enzyme-Linked Immunosorbent Assay
Observation

Keywords

  • A proliferation-inducing antigen
  • Arthritis
  • Autoimmune
  • B lymphocyte stimulator
  • T cell
  • TACI-Ig

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses. / Chang, Yan; Wu, Yujing; Wang, Di; Wei, Wei; Qin, Qiong; Xie, Guoxiong; Zhang, Lingling; Yan, Shangxue; Chen, Jingyu; Wang, Qingtong; Wu, Huaxun; Xiao, Feng; Sun, Wuyi; Jin, Juan; Wang, Wenxiang.

In: Rheumatology, Vol. 50, No. 5, keq404, 01.05.2011, p. 862-870.

Research output: Contribution to journalArticle

Chang, Y, Wu, Y, Wang, D, Wei, W, Qin, Q, Xie, G, Zhang, L, Yan, S, Chen, J, Wang, Q, Wu, H, Xiao, F, Sun, W, Jin, J & Wang, W 2011, 'Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses', Rheumatology, vol. 50, no. 5, keq404, pp. 862-870. https://doi.org/10.1093/rheumatology/keq404
Chang, Yan ; Wu, Yujing ; Wang, Di ; Wei, Wei ; Qin, Qiong ; Xie, Guoxiong ; Zhang, Lingling ; Yan, Shangxue ; Chen, Jingyu ; Wang, Qingtong ; Wu, Huaxun ; Xiao, Feng ; Sun, Wuyi ; Jin, Juan ; Wang, Wenxiang. / Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses. In: Rheumatology. 2011 ; Vol. 50, No. 5. pp. 862-870.
@article{0ba6ca5add4a4400a84e1ce2ed46e2d6,
title = "Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses",
abstract = "Objective: To investigate the effects of TACI-Ig, a recombinant fusion protein that modulates B- and T-cell activation by binding and neutralizing B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), in an established adjuvant-induced arthritis (AA) rat model. Methods: Rats with experimental arthritis were randomly separated into different groups and then treated with TACI-Ig (0.7, 2.1, 6.3 mg/kg), rhTNFR-Fc (2.8 mg/kg), MTX (0.5 mg/kg) or IgG-Fc (6.3 mg/kg), from Day 16 to Day 34 after immunization. Arthritis was evaluated by hind paw swelling, polyarthritis index and histopathological examination. Activities of BLyS, APRIL, IL-1β, IL-2, IL-10, TGF-β1, PGE 2, TNF-α, IFN-γ, immunoglobulin (Ig)G1, IgG2a, IgM and IgA were assessed by ELISA. Cluster of differentiation (CD)20 expression was detected by immunohistochemical analysis. Results: TACI-Ig (2.1, 6.3 mg/kg) treatment significantly reduced the severity of established arthritis using the methods of clinical observation and histopathological examination. TACI-Ig treatment inhibited expression of IgM, decreased the expression of BLyS and APRIL and regulated the balance of pro-inflammatory and anti-inflammatory cytokines in serum of AA rats. Immunohistochemical analysis demonstrated that CD20 production was reduced in spleen. Conclusions: Data presented here demonstrate that administration of TACI-Ig significantly attenuates progression of experimental arthritis, with reductions in inflammatory response and bone and joint destruction.",
keywords = "A proliferation-inducing antigen, Arthritis, Autoimmune, B lymphocyte stimulator, T cell, TACI-Ig",
author = "Yan Chang and Yujing Wu and Di Wang and Wei Wei and Qiong Qin and Guoxiong Xie and Lingling Zhang and Shangxue Yan and Jingyu Chen and Qingtong Wang and Huaxun Wu and Feng Xiao and Wuyi Sun and Juan Jin and Wenxiang Wang",
year = "2011",
month = "5",
day = "1",
doi = "10.1093/rheumatology/keq404",
language = "English (US)",
volume = "50",
pages = "862--870",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Therapeutic effects of TACI-Ig on rats with adjuvant-induced arthritis via attenuating inflammatory responses

AU - Chang, Yan

AU - Wu, Yujing

AU - Wang, Di

AU - Wei, Wei

AU - Qin, Qiong

AU - Xie, Guoxiong

AU - Zhang, Lingling

AU - Yan, Shangxue

AU - Chen, Jingyu

AU - Wang, Qingtong

AU - Wu, Huaxun

AU - Xiao, Feng

AU - Sun, Wuyi

AU - Jin, Juan

AU - Wang, Wenxiang

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Objective: To investigate the effects of TACI-Ig, a recombinant fusion protein that modulates B- and T-cell activation by binding and neutralizing B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), in an established adjuvant-induced arthritis (AA) rat model. Methods: Rats with experimental arthritis were randomly separated into different groups and then treated with TACI-Ig (0.7, 2.1, 6.3 mg/kg), rhTNFR-Fc (2.8 mg/kg), MTX (0.5 mg/kg) or IgG-Fc (6.3 mg/kg), from Day 16 to Day 34 after immunization. Arthritis was evaluated by hind paw swelling, polyarthritis index and histopathological examination. Activities of BLyS, APRIL, IL-1β, IL-2, IL-10, TGF-β1, PGE 2, TNF-α, IFN-γ, immunoglobulin (Ig)G1, IgG2a, IgM and IgA were assessed by ELISA. Cluster of differentiation (CD)20 expression was detected by immunohistochemical analysis. Results: TACI-Ig (2.1, 6.3 mg/kg) treatment significantly reduced the severity of established arthritis using the methods of clinical observation and histopathological examination. TACI-Ig treatment inhibited expression of IgM, decreased the expression of BLyS and APRIL and regulated the balance of pro-inflammatory and anti-inflammatory cytokines in serum of AA rats. Immunohistochemical analysis demonstrated that CD20 production was reduced in spleen. Conclusions: Data presented here demonstrate that administration of TACI-Ig significantly attenuates progression of experimental arthritis, with reductions in inflammatory response and bone and joint destruction.

AB - Objective: To investigate the effects of TACI-Ig, a recombinant fusion protein that modulates B- and T-cell activation by binding and neutralizing B-lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), in an established adjuvant-induced arthritis (AA) rat model. Methods: Rats with experimental arthritis were randomly separated into different groups and then treated with TACI-Ig (0.7, 2.1, 6.3 mg/kg), rhTNFR-Fc (2.8 mg/kg), MTX (0.5 mg/kg) or IgG-Fc (6.3 mg/kg), from Day 16 to Day 34 after immunization. Arthritis was evaluated by hind paw swelling, polyarthritis index and histopathological examination. Activities of BLyS, APRIL, IL-1β, IL-2, IL-10, TGF-β1, PGE 2, TNF-α, IFN-γ, immunoglobulin (Ig)G1, IgG2a, IgM and IgA were assessed by ELISA. Cluster of differentiation (CD)20 expression was detected by immunohistochemical analysis. Results: TACI-Ig (2.1, 6.3 mg/kg) treatment significantly reduced the severity of established arthritis using the methods of clinical observation and histopathological examination. TACI-Ig treatment inhibited expression of IgM, decreased the expression of BLyS and APRIL and regulated the balance of pro-inflammatory and anti-inflammatory cytokines in serum of AA rats. Immunohistochemical analysis demonstrated that CD20 production was reduced in spleen. Conclusions: Data presented here demonstrate that administration of TACI-Ig significantly attenuates progression of experimental arthritis, with reductions in inflammatory response and bone and joint destruction.

KW - A proliferation-inducing antigen

KW - Arthritis

KW - Autoimmune

KW - B lymphocyte stimulator

KW - T cell

KW - TACI-Ig

UR - http://www.scopus.com/inward/record.url?scp=79955161433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955161433&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keq404

DO - 10.1093/rheumatology/keq404

M3 - Article

C2 - 21186171

AN - SCOPUS:79955161433

VL - 50

SP - 862

EP - 870

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 5

M1 - keq404

ER -